Alcohol dehydrogenase and aldehyde dehydrogenase polymorphisms and colorectal cancer: The Fukuoka Colorectal Cancer Study

Guang Yin, Suminori Kono, Kengo Toyomura, Malcolm A. Moore, June Nagano, Tetsuya Mizoue, Ryuichi Mibu, Masao Tanaka, Yoshihiro Kakeji, Yoshihiko Maehara, Takeshi Okamura, Koji Ikejiri, Kitaroh Futami, Yohichi Yasunami, Takafumi Maekawa, Kenji Takenaka, Hitoshi Ichimiya, Nobutoshi Imaizumi

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Alcohol dehydrogenase and aldehyde dehydrogenase are key enzymes in alcohol metabolism and therefore may be of importance to colorectal cancer development. The present case-control study was conducted to determine the influence of ADH2, ADH3 and ALDH2 polymorphisms in Fukuoka, Japan, with 685 incident cases of histologically confirmed colorectal adenocarcinomas and 778 community controls selected randomly from the study area. Alcohol use was ascertained by in-person interview. Statistical adjustment was made for sex, age class, area, and alcohol use. Individuals with the allele 47Arg of the ADH2 polymorphism (slow metabolizers) had a statistically significant increase in risk, with an adjusted OR of 1.32 (95% CI = 1.07-1.63), compared with those having the ADH2* 47His/His genotype. This association was not affected by the level of alcohol consumption. The ADH3 polymorphism showed no measurable association with the risk of colorectal cancer on either overall analysis or stratified analysis with alcohol use. The heterozygous ALDH2* 487Glu/Lys genotype was not associated with an increase in the risk of colorectal cancer (adjusted OR 0.89, 95% CI = 0.71-1.13) compared with the ALDH2 * 487Glu/Glu genotype. Rather unexpectedly, the homozygous ALDH2* 487Lys/Lys genotype was related to a statistically significantly decreased risk of colorectal cancer (adjusted OR 0.55, 95% CI = 0.33-0.93). It is unlikely that acetaldehyde metabolism determined by ALDH2 polymorphism contributes to the risk of colorectal cancer, whereas the role of ADH2 polymorphism deserves further investigation.

Original languageEnglish
Pages (from-to)1248-1253
Number of pages6
JournalCancer Science
Volume98
Issue number8
DOIs
Publication statusPublished - Aug 1 2007

Fingerprint

Aldehyde Dehydrogenase
Alcohol Dehydrogenase
Colorectal Neoplasms
Genotype
Alcohols
Social Adjustment
Acetaldehyde
Alcohol Drinking
Case-Control Studies
Japan
Adenocarcinoma
Alleles
Interviews
Enzymes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Alcohol dehydrogenase and aldehyde dehydrogenase polymorphisms and colorectal cancer : The Fukuoka Colorectal Cancer Study. / Yin, Guang; Kono, Suminori; Toyomura, Kengo; Moore, Malcolm A.; Nagano, June; Mizoue, Tetsuya; Mibu, Ryuichi; Tanaka, Masao; Kakeji, Yoshihiro; Maehara, Yoshihiko; Okamura, Takeshi; Ikejiri, Koji; Futami, Kitaroh; Yasunami, Yohichi; Maekawa, Takafumi; Takenaka, Kenji; Ichimiya, Hitoshi; Imaizumi, Nobutoshi.

In: Cancer Science, Vol. 98, No. 8, 01.08.2007, p. 1248-1253.

Research output: Contribution to journalArticle

Yin, G, Kono, S, Toyomura, K, Moore, MA, Nagano, J, Mizoue, T, Mibu, R, Tanaka, M, Kakeji, Y, Maehara, Y, Okamura, T, Ikejiri, K, Futami, K, Yasunami, Y, Maekawa, T, Takenaka, K, Ichimiya, H & Imaizumi, N 2007, 'Alcohol dehydrogenase and aldehyde dehydrogenase polymorphisms and colorectal cancer: The Fukuoka Colorectal Cancer Study', Cancer Science, vol. 98, no. 8, pp. 1248-1253. https://doi.org/10.1111/j.1349-7006.2007.00519.x
Yin, Guang ; Kono, Suminori ; Toyomura, Kengo ; Moore, Malcolm A. ; Nagano, June ; Mizoue, Tetsuya ; Mibu, Ryuichi ; Tanaka, Masao ; Kakeji, Yoshihiro ; Maehara, Yoshihiko ; Okamura, Takeshi ; Ikejiri, Koji ; Futami, Kitaroh ; Yasunami, Yohichi ; Maekawa, Takafumi ; Takenaka, Kenji ; Ichimiya, Hitoshi ; Imaizumi, Nobutoshi. / Alcohol dehydrogenase and aldehyde dehydrogenase polymorphisms and colorectal cancer : The Fukuoka Colorectal Cancer Study. In: Cancer Science. 2007 ; Vol. 98, No. 8. pp. 1248-1253.
@article{183393a622a140c699ea8c8585f3c1ab,
title = "Alcohol dehydrogenase and aldehyde dehydrogenase polymorphisms and colorectal cancer: The Fukuoka Colorectal Cancer Study",
abstract = "Alcohol dehydrogenase and aldehyde dehydrogenase are key enzymes in alcohol metabolism and therefore may be of importance to colorectal cancer development. The present case-control study was conducted to determine the influence of ADH2, ADH3 and ALDH2 polymorphisms in Fukuoka, Japan, with 685 incident cases of histologically confirmed colorectal adenocarcinomas and 778 community controls selected randomly from the study area. Alcohol use was ascertained by in-person interview. Statistical adjustment was made for sex, age class, area, and alcohol use. Individuals with the allele 47Arg of the ADH2 polymorphism (slow metabolizers) had a statistically significant increase in risk, with an adjusted OR of 1.32 (95{\%} CI = 1.07-1.63), compared with those having the ADH2* 47His/His genotype. This association was not affected by the level of alcohol consumption. The ADH3 polymorphism showed no measurable association with the risk of colorectal cancer on either overall analysis or stratified analysis with alcohol use. The heterozygous ALDH2* 487Glu/Lys genotype was not associated with an increase in the risk of colorectal cancer (adjusted OR 0.89, 95{\%} CI = 0.71-1.13) compared with the ALDH2 * 487Glu/Glu genotype. Rather unexpectedly, the homozygous ALDH2* 487Lys/Lys genotype was related to a statistically significantly decreased risk of colorectal cancer (adjusted OR 0.55, 95{\%} CI = 0.33-0.93). It is unlikely that acetaldehyde metabolism determined by ALDH2 polymorphism contributes to the risk of colorectal cancer, whereas the role of ADH2 polymorphism deserves further investigation.",
author = "Guang Yin and Suminori Kono and Kengo Toyomura and Moore, {Malcolm A.} and June Nagano and Tetsuya Mizoue and Ryuichi Mibu and Masao Tanaka and Yoshihiro Kakeji and Yoshihiko Maehara and Takeshi Okamura and Koji Ikejiri and Kitaroh Futami and Yohichi Yasunami and Takafumi Maekawa and Kenji Takenaka and Hitoshi Ichimiya and Nobutoshi Imaizumi",
year = "2007",
month = "8",
day = "1",
doi = "10.1111/j.1349-7006.2007.00519.x",
language = "English",
volume = "98",
pages = "1248--1253",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Alcohol dehydrogenase and aldehyde dehydrogenase polymorphisms and colorectal cancer

T2 - The Fukuoka Colorectal Cancer Study

AU - Yin, Guang

AU - Kono, Suminori

AU - Toyomura, Kengo

AU - Moore, Malcolm A.

AU - Nagano, June

AU - Mizoue, Tetsuya

AU - Mibu, Ryuichi

AU - Tanaka, Masao

AU - Kakeji, Yoshihiro

AU - Maehara, Yoshihiko

AU - Okamura, Takeshi

AU - Ikejiri, Koji

AU - Futami, Kitaroh

AU - Yasunami, Yohichi

AU - Maekawa, Takafumi

AU - Takenaka, Kenji

AU - Ichimiya, Hitoshi

AU - Imaizumi, Nobutoshi

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Alcohol dehydrogenase and aldehyde dehydrogenase are key enzymes in alcohol metabolism and therefore may be of importance to colorectal cancer development. The present case-control study was conducted to determine the influence of ADH2, ADH3 and ALDH2 polymorphisms in Fukuoka, Japan, with 685 incident cases of histologically confirmed colorectal adenocarcinomas and 778 community controls selected randomly from the study area. Alcohol use was ascertained by in-person interview. Statistical adjustment was made for sex, age class, area, and alcohol use. Individuals with the allele 47Arg of the ADH2 polymorphism (slow metabolizers) had a statistically significant increase in risk, with an adjusted OR of 1.32 (95% CI = 1.07-1.63), compared with those having the ADH2* 47His/His genotype. This association was not affected by the level of alcohol consumption. The ADH3 polymorphism showed no measurable association with the risk of colorectal cancer on either overall analysis or stratified analysis with alcohol use. The heterozygous ALDH2* 487Glu/Lys genotype was not associated with an increase in the risk of colorectal cancer (adjusted OR 0.89, 95% CI = 0.71-1.13) compared with the ALDH2 * 487Glu/Glu genotype. Rather unexpectedly, the homozygous ALDH2* 487Lys/Lys genotype was related to a statistically significantly decreased risk of colorectal cancer (adjusted OR 0.55, 95% CI = 0.33-0.93). It is unlikely that acetaldehyde metabolism determined by ALDH2 polymorphism contributes to the risk of colorectal cancer, whereas the role of ADH2 polymorphism deserves further investigation.

AB - Alcohol dehydrogenase and aldehyde dehydrogenase are key enzymes in alcohol metabolism and therefore may be of importance to colorectal cancer development. The present case-control study was conducted to determine the influence of ADH2, ADH3 and ALDH2 polymorphisms in Fukuoka, Japan, with 685 incident cases of histologically confirmed colorectal adenocarcinomas and 778 community controls selected randomly from the study area. Alcohol use was ascertained by in-person interview. Statistical adjustment was made for sex, age class, area, and alcohol use. Individuals with the allele 47Arg of the ADH2 polymorphism (slow metabolizers) had a statistically significant increase in risk, with an adjusted OR of 1.32 (95% CI = 1.07-1.63), compared with those having the ADH2* 47His/His genotype. This association was not affected by the level of alcohol consumption. The ADH3 polymorphism showed no measurable association with the risk of colorectal cancer on either overall analysis or stratified analysis with alcohol use. The heterozygous ALDH2* 487Glu/Lys genotype was not associated with an increase in the risk of colorectal cancer (adjusted OR 0.89, 95% CI = 0.71-1.13) compared with the ALDH2 * 487Glu/Glu genotype. Rather unexpectedly, the homozygous ALDH2* 487Lys/Lys genotype was related to a statistically significantly decreased risk of colorectal cancer (adjusted OR 0.55, 95% CI = 0.33-0.93). It is unlikely that acetaldehyde metabolism determined by ALDH2 polymorphism contributes to the risk of colorectal cancer, whereas the role of ADH2 polymorphism deserves further investigation.

UR - http://www.scopus.com/inward/record.url?scp=34347260325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347260325&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2007.00519.x

DO - 10.1111/j.1349-7006.2007.00519.x

M3 - Article

C2 - 17517051

AN - SCOPUS:34347260325

VL - 98

SP - 1248

EP - 1253

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 8

ER -